Showing results (141-150 of 148) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 148 results.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|August 6, 2025
Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter AnalysisTomomitsu Matono, Toshifumi Tada, Takashi Kumada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 10, 2026
Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus BevacizumabKazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 26, 2026
Lymphocyte-Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus TremelimumabTomomitsu Matono, Toshifumi Tada, Atsushi Hiraoka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 21, 2026
Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus BevacizumabFujimasa Tada, Atsushi Hiraoka, Hideko Ohama, et al.
Hepatology (Baltimore, Md.)|May 6, 2026
Optimizing bevacizumab exposure in atezolizumab-based therapy for unresectable hepatocellular carcinoma: A nationwide real-world studyKaho Aoe, Toshifumi Tada, Atsushi Hiraoka, et al.
Journal of Gastroenterology and Hepatology|May 23, 2026
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA TrialTomomitsu Matono, Toshifumi Tada, Atsushi Hiraoka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 9, 2026
Efficacy and Safety of Atezolizumab Plus Bevacizumab Versus Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma in Patients With Child-Pugh Class B: A Real-World StudyHideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Liver Cancer|June 3, 2026
Real-World Comparison of First-Line Atezolizumab plus Bevacizumab and Durvalumab plus Tremelimumab for Unresectable Hepatocellular CarcinomaAtsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, et al.
Pageof 15